Screener
Amphastar Pharmaceuticals AMPH Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $1,743,766 | $1,629,299 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $251,371 | $148,348 |
| Income taxes payable | 546 | 239 |
| Current portion of long-term debt | 2,488 | 1,641 |
| Current portion of operating lease liabilities | 8,800 | 7,928 |
| Total current liabilities | 263,205 | 158,156 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's accounts payable?
- Amphastar Pharmaceuticals (AMPH) reported accounts payable of $251.37M in Q2 2026.
- How has Amphastar Pharmaceuticals's accounts payable changed year-over-year?
- Amphastar Pharmaceuticals's accounts payable increased by 50.9% year-over-year, from $166.55M to $251.37M.
- What is the long-term trend for Amphastar Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's accounts payable has grown at a 9.2% compound annual growth rate (CAGR), from $95.5M to $148.35M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Amphastar Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude